Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Macy's Inc (M) vs Revvity Inc (RVTY) Price & Performance

Macy's IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Macy's Inc vs Revvity Inc — how do they compare? Macy's Inc trades at $23.33 (market cap $6.13B), while Revvity Inc trades at $110.43 (market cap $11.87B). The key difference: Revvity Inc is the larger of the two by market cap, and Macy's Inc pays the higher dividend (3.29%). Which is the better fit depends on your goals.

MRVTY
Market Cap
$6.13B$11.87B
Sector
Consumer CyclicalTechnology
52-Week High
$25.96$117.75
52-Week Low
$11.90$82.26
Enterprise Value
$9.95B$14.36B
Dividend Yield
3.29%0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Macy's Inc

Macy's (M) trades at $23.39, down 1.22% on the day, with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. Positive sentiment is driven by the 'Bold New Chapter' turnaround strategy, with Berkshire Hathaway's new 3.04 million-share position adding institutional confidence.

The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 6% upside potential. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from store closures and macroeconomic sensitivity. The stock presents value characteristics with growth catalysts from operational improvements.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.

The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY